免疫抑制小鼠播散性念珠菌病模型中评估伏立康唑、伊曲康唑、氟康唑和阿尼芬净治疗新发念珠菌属耳念珠菌感染的疗效。
Efficacy of Voriconazole, Isavuconazole, Fluconazole, and Anidulafungin in the Treatment of Emerging Candida auris Using an Immunocompromised Murine Model of Disseminated Candidiasis.
机构信息
Center for Medical Mycology, Department of Dermatology, Case Western Reserve Universitygrid.67105.35, Cleveland, Ohio, USA.
Pfizer Inc., New York, New York, USA.
出版信息
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0054921. doi: 10.1128/AAC.00549-21.
Abstract
Antifungal activity of anidulafungin, voriconazole, isavuconazole, and fluconazole in the treatment of Candida auris was determined and . MICs for anidulafungin, voriconazole, isavuconazole, fluconazole, and amphotericin B were 0.5, 1, >64, 0.25, and 4 μg/ml, respectively. Significant efficacy was observed in the anidulafungin- and voriconazole-treated groups in survival and reduction in kidney tissue fungal burden compared to that in the untreated group ( values of <0.001 and 0.044, respectively). Our data showed that anidulafungin and voriconazole had comparable efficacies against C. auris, whereas isavuconazole did not show significant activity.
摘要
测定了安尼拉fungin、伏立康唑、伊曲康唑和氟康唑治疗耳念珠菌的抗真菌活性，。安尼拉fungin、伏立康唑、伊曲康唑、氟康唑和两性霉素 B 的 MIC 分别为 0.5、1、>64、0.25 和 4μg/ml。与未治疗组相比，安尼拉fungin 和伏立康唑治疗组的存活率和肾脏组织真菌负荷均有显著改善（值分别为<0.001 和 0.044）。我们的数据表明，安尼拉fungin 和伏立康唑对耳念珠菌具有相当的疗效，而伊曲康唑则没有显著的活性。
相似文献
1
Efficacy of Voriconazole, Isavuconazole, Fluconazole, and Anidulafungin in the Treatment of Emerging Candida auris Using an Immunocompromised Murine Model of Disseminated Candidiasis.免疫抑制小鼠播散性念珠菌病模型中评估伏立康唑、伊曲康唑、氟康唑和阿尼芬净治疗新发念珠菌属耳念珠菌感染的疗效。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0054921. doi: 10.1128/AAC.00549-21.
2
Evaluation of Synergistic Activity of Isavuconazole or Voriconazole plus Anidulafungin and the Occurrence and Genetic Characterization of Candida auris Detected in a Surveillance Program.在一项监测计划中对艾沙康唑或伏立康唑联合阿尼芬净的协同活性以及耳念珠菌的发生情况和基因特征进行评估。
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02031-20.
3
and Antifungal Activity of AmBisome Compared to Conventional Amphotericin B and Fluconazole against Candida auris.两性霉素 B 脂质体与常规两性霉素 B 和氟康唑对耳念珠菌的抗真菌活性比较。
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00306-21.
4
Pathogenicity Evaluation on Fluconazole-Resistant Candida auris Clade V in Murine Model.氟康唑耐药耳念珠菌V型在小鼠模型中的致病性评估
Mycopathologia. 2025 Jun 24;190(4):58. doi: 10.1007/s11046-025-00963-5.
5
Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.艾沙康唑、伏立康唑和氟康唑在热带念珠菌和克柔念珠菌播散性感染的暂时性中性粒细胞减少小鼠模型中的疗效。
J Antimicrob Chemother. 2009 Jan;63(1):161-6. doi: 10.1093/jac/dkn431. Epub 2008 Nov 13.
6
Evaluation of the MIC test strips for antifungal susceptibility testing of () using a representative international collection of isolates.使用具有代表性的国际分离株集合评估用于（）抗真菌药敏试验的MIC测试条。
J Clin Microbiol. 2025 Aug 13;63(8):e0039925. doi: 10.1128/jcm.00399-25. Epub 2025 Jul 3.
7
Treatment of invasive candidal infections: systematic review and meta-analysis.侵袭性念珠菌感染的治疗：系统评价与荟萃分析
Mayo Clin Proc. 2008 Sep;83(9):1011-21. doi: 10.4065/83.9.1011.
8
A 40-year antifungal susceptibility surveillance of Talaromyces marneffei (1984-2024) at a tertiary hospital in Guangxi, China.中国广西一家三级医院对马尔尼菲篮状菌的40年（1984 - 2024年）抗真菌药敏监测
Med Mycol. 2025 Jun 5;63(6). doi: 10.1093/mmy/myaf047.
9
Epidemiology and antifungal susceptibility of fungal infections from 2018 to 2021 in Shandong, eastern China: A report from the SPARSS program.2018 年至 2021 年中国东部山东省真菌感染的流行病学和抗真菌药物敏感性：SPARSS 项目报告。
Indian J Med Microbiol. 2024 Jan-Feb;47:100518. doi: 10.1016/j.ijmmb.2023.100518. Epub 2023 Dec 5.
10
Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.艾沙康唑及其他唑类药物对念珠菌临床分离株和具有已知唑类耐药机制的酵母模型系统的活性。
Antimicrob Agents Chemother. 2015 Oct 19;60(1):229-38. doi: 10.1128/AAC.02157-15. Print 2016 Jan.
引用本文的文献
1
Perspectives on the Use of Echinocandins in the Neonatal Intensive Care Unit.新生儿重症监护病房中棘白菌素类药物的应用前景
Antibiotics (Basel). 2024 Dec 12;13(12):1209. doi: 10.3390/antibiotics13121209.
2
Recent Challenges in Diagnosis and Treatment of Invasive Candidiasis in Neonates.新生儿侵袭性念珠菌病诊断与治疗的近期挑战
Children (Basel). 2024 Sep 30;11(10):1207. doi: 10.3390/children11101207.
3
Meeting the Therapeutic Challenges of Emergent and Rare Invasive Fungal Diseases Through Novel Clinical Trial Designs.通过新型临床试验设计应对紧急和罕见侵袭性真菌病的治疗挑战。
Open Forum Infect Dis. 2024 Jun 17;11(6):ofae257. doi: 10.1093/ofid/ofae257. eCollection 2024 Jun.
本文引用的文献
1
and Antifungal Activity of AmBisome Compared to Conventional Amphotericin B and Fluconazole against Candida auris.两性霉素 B 脂质体与常规两性霉素 B 和氟康唑对耳念珠菌的抗真菌活性比较。
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00306-21.
2
Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against .依布康唑，一种正在研发的新型口服三萜类抗真菌药物：抗真菌活性概述
Front Cell Infect Microbiol. 2021 Mar 11;11:642358. doi: 10.3389/fcimb.2021.642358. eCollection 2021.
3
Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Infections.依布雷克芬净：一种正在研发用于治疗感染的新型口服三萜类抗真菌药物。
Antibiotics (Basel). 2020 Aug 25;9(9):539. doi: 10.3390/antibiotics9090539.
4
Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an Guinea Pig Cutaneous Infection Model.伊柏呋喃（SCY-078）在豚鼠皮肤感染模型中抗耳念珠菌的疗效。
Antimicrob Agents Chemother. 2020 Sep 21;64(10). doi: 10.1128/AAC.00854-20.
5
Candida auris Isolates Resistant to Three Classes of Antifungal Medications - New York, 2019.耳念珠菌对三类抗真菌药物耐药——纽约，2019 年。
MMWR Morb Mortal Wkly Rep. 2020 Jan 10;69(1):6-9. doi: 10.15585/mmwr.mm6901a2.
6
Activity of Ibrexafungerp (SCY-078) against Isolates as Determined by EUCAST Methodology and Comparison with Activity against and and with the Activities of Six Comparator Agents.依布硒康唑（SCY-078）对 EUCAST 方法学确定的分离株的活性及与对 和 的活性比较，以及与六种对照药物的活性比较。
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.02136-19.
7
Molecular Diagnostics in the Times of Surveillance for .监测时代的分子诊断学 （原文不完整，翻译至此）
J Fungi (Basel). 2019 Aug 20;5(3):77. doi: 10.3390/jof5030077.
8
Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.伊曲康唑与卡泊芬净治疗念珠菌血症和其他侵袭性念珠菌感染：ACTIVE 试验。
Clin Infect Dis. 2019 May 30;68(12):1981-1989. doi: 10.1093/cid/ciy827.
9
Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model.评估新型棘白菌素类药物瑞他康唑在免疫抑制小鼠模型中治疗播散性耳念珠菌感染的疗效。
J Antimicrob Chemother. 2018 Aug 1;73(8):2085-2088. doi: 10.1093/jac/dky153.
10
An outbreak due to Candida auris with prolonged colonisation and candidaemia in a tertiary care European hospital.一家三级保健欧洲医院中，由于耳念珠菌导致的暴发感染，患者出现长时间定植和念珠菌血症。
Mycoses. 2018 Jul;61(7):498-505. doi: 10.1111/myc.12781. Epub 2018 Jun 8.
Zotero 插件